Đang chuẩn bị liên kết để tải về tài liệu:
Báo cáo y học: "Garden of therapeutic delights: new targets in rheumatic diseases"

Tuyển tập các báo cáo nghiên cứu về y học được đăng trên tạp chí y học General Psychiatry cung cấp cho các bạn kiến thức về ngành y đề tài: Garden of therapeutic delights: new targets in rheumatic diseases. | Available online http arthritis-research.eom content 11 1 206 Review Garden of therapeutic delights new targets in rheumatic diseases Jean M Waldburger and Gary S Firestein Division of Rheumatology Allergy and Immunology University of California San Diego School of Medicine Mail Code 0656 9500 Gilman Drive La Jolla CA 92093 USA Corresponding author Gary S Firestein gfirestein@ucsd.edu Published 30 January 2009 This article is online at http arthritis-research.com content 11 1 206 2009 BioMed Central Ltd Arthritis Research Therapy 2009 11 206 doi 10.1186 ar2556 Abstract Advances in our understanding of the cellular and molecular mechanisms in rheumatic disease fostered the advent of the targeted therapeutics era. Intense research activity continues to increase the number of potential targets at an accelerated pace. In this review examples of promising targets and agents that are at various stages of clinical development are described. Cytokine inhibition remains at the forefront with the success of tumor necrosis factor blockers and biologics that block interleukin-6 IL-6 IL-17 IL-12 and IL-23 and other cytokines are on the horizon. After the success of rituximab and abatacept other cell-targeted approaches that inhibit or deplete lymphocytes have moved forward such as blocking BAFF BLyS B-cell activation factor of the tumor necrosis factor family B-lymphocyte stimulator and APRIL a proliferation-inducing ligand or suppressing T-cell activation with costimulation molecule blockers. Small-molecule inhibitors might eventually challenge the dominance of biologics in the future. In addition to plasma membrane G protein-coupled chemokine receptors small molecules can be designed to block intracellular enzymes that control signaling pathways. Inhibitors of tyrosine kinases expressed in lymphocytes such as spleen tyrosine kinase and Janus kinase are being tested in autoimmune diseases. Inactivation of the more broadly expressed mitogen-activated protein kinases could .